NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

TransEnterix Senhance Surgical System
RTP medical device company TransEnterix is establishing the first Asia-Pacific training center for its Senhance Surgical System at the Saitama Medical University International Center in Tokyo.
Biogen logo
Biogen announces a $250 million, 20-year initiative – Healthy Climate, Healthy Lives – to eliminate fossil fuel emissions across all its operations by 2040.
NIIMBL testing 2020
Getting accurate, timely information on COVID-19 cases is one of the major challenges facing policymakers as they make decisions about public health and the economy. Researchers at North Carolina State University are embarking on a project aimed at making sure test kits are available where they are most needed, so that policymakers have the information they need.
GRAIL logo
The innovative California-based cancer-detection company GRAIL, Inc., which is establishing a $100 million-plus facility in Research Triangle Park, is preparing to go public.
AgEye indoor farm photo
Raleigh-based AgEye Technologies, which typically provides its indoor farming customers AI-powered cameras, sensors and predictive analytics, has added its pandemic-beating “plant scientist in a box” to its portfolio.
iStock photo of DDT spraying in India
A researcher in the Brody School of Medicine at East Carolina University is using an NCBiotech grant to study the human and environmental safety of NoPest, an ECU-created novel pesticide aimed at mosquito control.
LabCorp logo
Burlington-based LabCorp has developed the first testing method to simultaneously detect for COVID-19, influenza A / B, and respiratory syncytial virus (RSV) just in time for the upcoming flu season.
opaganib
RedHill Biopharma, an Israeli company with U.S. headquarters in Raleigh, says one of its drug candidates, opaganib, completely inhibited the replication of the coronavirus that causes COVID-19 in a laboratory study.
Novartis Gene Therapies site in Durham
Novartis has renamed its previously acquired AveXis gene therapy arm. It's now called Novartis Gene Therapies.
GeneCoda logo
GeneCoda executive Don Alexander shares results of a 100-company survey his team conducted to understand the COVID-19 impact on life sciences businesses.
CREID logo
RTI International and Duke University’s Human Vaccine Institute will collaborate in a global project to identify viruses and other pathogens in wildlife that could cause disease in people, such as the coronavirus responsible for the COVID-19 pandemic
BioCryst logo
Durham’s BioCryst Pharmaceuticals has landed a new federal contract totaling $44 million and added some $3 million to an existing contract to support the development of galidesivir as a possible COVID-19 treatment.
bluebird bio photo
bluebird bio, a global gene therapy company with a new manufacturing facility in Durham, has unveiled positive results in clinical trials of its treatment for boys with a rare and deadly neurological disorder.
Covidentify feature image for smart watches
News of the first U.S. coronavirus case hit the American public on Tuesday, Jan. 21. For Jessilyn Dunn, PhD, assistant professor in the Departments of Biomedical Engineering and Biostatistics and Bioinformatics at Duke University and director of the Duke BIG IDEAs Lab, the infection in Washington State was a cue to launch a new study⁠—CovIdentify.
APIE logo
RTP's APIE Therapeutics has signed a licensing agreement with RTI International to develop a class of RTI-developed compounds targeting heart failure and lung disease.